CorMedix Inc., a Berkeley Heights-based biopharmaceutical company, announced a number of leadership changes this week, including the retirement of its CEO.
The company, which focuses on therapeutic products for infectious and inflammatory diseases, said CEO Khoso Baluch is retiring, and has also resigned from the board of directors. In addition, John Armstrong, executive vice president for technical operations, is retiring.
Dr. Matt David, EVP and chief financial officer, will serve as interim CEO, while remaining in his CFO post. Phoebe Mounts, general counsel and head of regulatory, compliance and legal, will have direct authority over the Technical Operations Group.
“On behalf of the entire board, I thank Khoso and Jack for their dedicated service and contributions to CorMedix,” board Chairman Myron Kaplan said in a prepared statement. “Khoso has been instrumental in refocusing the company and guiding it strategically while building a highly experienced executive team. Matt’s energy and leadership, with the support of CorMedix’s board of directors and experienced management team, enable him to continue the important work underway to progress (lead product) DefenCath, while the CEO search is ongoing.”
The board of the company is initiating a search process for a new CEO, and Baluch will serve in an advisory capacity during the transition.